Promacta (eltrombopag) - Novartis
Prevymis (letermovir) - Merck (MSD)
Bidirectional Temporal Association Between Cytomegalovirus Reactivation and Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Real-World Cohort Study. (PubMed, Viruses) - Aug 28, 2026 - "CMV reactivation was highly prevalent after allo-HSCT and frequently preceded GVHD, supporting a bidirectional temporal relationship between these complications. Older donor age was associated with both CMV reactivation and GVHD. Although survival did not significantly differ according to CMV or GVHD status in this day-100 landmark cohort, clinically important CMV-related complications, including end-organ disease and platelet engraftment failure requiring eltrombopag, remained common. These findings indicate that a standardized pre-emptive strategy did not completely prevent CMV-associated morbidity. Because letermovir was not evaluated in this cohort, any potential benefit of prophylaxis should be interpreted as an inference from external evidence rather than as a direct finding of this study. Prospective multicenter studies incorporating immune reconstitution analyses are warranted." 
Journal • Real-world evidence • Retrospective data • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Oncology • Transplantation
http://www.ncbi.nlm.nih.gov/pubmed/42655692
 
Ahmet Ceylan; Bircan Kayaaslan; Derya Kayard?; Fahir Öztürk; Funda Ceran; Gülsüm Özet; Gülten Korkmaz; Mehmet Sezgin Pepeler; Merve Ecem Erdo?an Yön
 
Aug 28, 2026
 
Prev Next